Alternatively, the CRISPR/Cas9 system has been used to upregulate the expression of chemokine receptors such as CXCR2 and IL-2 on NK cells, thereby leading to increased migration to tumor sites, enhanced proliferation and improved cell killing in a preclinical colon cancer model [122]. This evidence concerns the gene IL2 and neoplasm.